Imperagen, a UK-based biotech startup, has raised $5 million in seed funding to develop its quantum physics and AI-driven platform for enzyme engineering. The company is focused on making enzyme design faster, more efficient, and more cost-effective compared to traditional laboratory-based trial-and-error methods used in biotechnology and pharmaceutical development.
The startup uses a combination of quantum physics-based simulations, machine learning models, and laboratory automation to predict how enzyme variants will behave before they are physically tested. This closed-loop system allows computational predictions to be validated in automated labs, with the resulting experimental data continuously improving the AI models over time.
Imperagen’s approach is designed to significantly speed up enzyme engineering, which plays a critical role in industries such as pharmaceuticals, food production, biofuels, and sustainable chemical manufacturing. By reducing the need for extensive physical testing, the technology aims to lower development costs and improve the success rate of enzyme-based innovation.
The funding round, led by PXN Ventures with participation from IQ Capital and Northern Gritstone, will support the expansion of the company’s research capabilities, AI development, and laboratory infrastructure. The capital will also be used to strengthen its go-to-market strategy and scale partnerships across biotech and industrial sectors.
Imperagen’s development reflects a broader trend in deep-tech biotech investment, where AI, automation, and quantum computing are increasingly being combined to solve complex scientific and industrial challenges. Investors see enzyme engineering as a high-impact area with applications in sustainability, healthcare, and next-generation manufacturing processes.
